Almost every founder raising a first round hits the same fork in the road: convertible notes vs equity. Choose the wrong instrument and you can give away more of your company than you intended, create securities-law headaches, or clutter your cap table before you ever reach a Series A. This guide walks through how the choice actually works and the five traps that cost founders the most money and leverage.
At Howard East, we sit across the table from founders and investors negotiating these deals. The convertible notes vs equity question is rarely about which structure is “better” in the abstract. It is about stage, speed, negotiating leverage, and what you are willing to give up today in exchange for capital now.
What You’ll Learn
What “Convertible Notes vs Equity” Really Means
The convertible notes vs equity debate is really a debate about when you price your company. In a priced equity round, you agree on a valuation today and sell shares at that price. With a convertible instrument, you take the money now and price the deal later, usually at the next round.
Convertible instruments come in two flavors. A convertible note is debt that converts into stock. A SAFE (Simple Agreement for Future Equity) is not debt at all. Both let you defer the valuation fight, which is why early-stage founders reach for them so often.
So the practical question is priced equity versus deferred-pricing convertibles. Each path sets a different trajectory for ownership, investor rights, and taxes.
How a Priced Equity Round Works
In a priced round, you set a pre-money valuation, issue shares (usually preferred stock for institutional investors), and the investor wires funds in exchange for a fixed percentage of the company. Ownership is settled the day the deal closes.
The upside is clarity. Everyone knows exactly who owns what, there is no “overhang” of instruments waiting to convert, and the holding period for tax benefits like qualified small business stock can begin immediately. Investors also receive negotiated rights: board seats, protective provisions, and information rights.
The cost is time and money. Priced rounds require a term sheet, a 409A and preferred-stock valuation, and a stack of financing documents. You also have to agree on a number early, when your leverage may be weakest. For a first check from people who know you, a full priced round is often overkill — see our guide to the friends and family round.
How Convertible Notes and SAFEs Work
A convertible note is a loan. It carries an interest rate (commonly 4% to 8%), a maturity date (often 18 to 24 months), and terms that govern how it turns into equity — typically a valuation cap and a conversion discount of 10% to 20%. When the next priced round closes, the note converts into shares at the more favorable of the cap or the discount.
A SAFE strips out the debt features. There is no interest and no maturity date, just a valuation cap and/or discount. The post-money SAFE fixes the investor’s ownership percentage at signing, which gives investors certainty but pushes more dilution onto founders. SAFEs have become the market default: according to Carta, SAFEs made up roughly 90% of pre-seed rounds in early 2025, and cap-only SAFEs dominate.
Convertibles are fast and cheap, but they stack. Raise on three SAFEs with different caps and you may not know your true fully diluted ownership until they all convert. For the mechanics of each instrument, see our explainer on convertible notes and SAFEs, and read outstanding vs. fully diluted ownership before you sign anything.
When to Choose Convertible Notes vs Equity
There is no universal answer to convertible notes vs equity, but there is a reliable framework. Weigh stage, speed, valuation certainty, and how much structure your investors expect.
| Factor | Lean Convertible (Note/SAFE) | Lean Priced Equity |
|---|---|---|
| Stage | Pre-seed / seed | Seed lead or Series A |
| Speed | Need to close in days | Weeks of diligence acceptable |
| Valuation | Too early to price fairly | Market comps support a number |
| Investor | Angels, rolling checks | Fund taking a board seat |
| Legal cost | Minimal | Higher, but comprehensive |
As a rule of thumb: if you are raising a small amount quickly from investors who trust you, a SAFE or note usually wins. Once a lead investor wants governance rights and the round is large enough to justify the legal spend, a priced equity round is the cleaner long-term choice.
The Securities-Law Layer: Reg D and Accredited Investors
Whichever path you pick, you are selling securities. Shares, convertible notes, and SAFEs are all securities that must be registered with the SEC or fit an exemption. Most startups rely on Regulation D. Under Rule 506(b), you cannot generally solicit or advertise, but you can raise from an unlimited number of accredited investors plus up to 35 sophisticated non-accredited investors. Rule 506(c) lets you advertise openly, but every investor must be accredited and you must take reasonable steps to verify it.
An individual generally qualifies as an accredited investor with a net worth over $1 million excluding a primary residence, or income over $200,000 (or $300,000 jointly) in the last two years. We cover the details in our post on accredited investor rules.
One trap specific to convertible notes: because they are debt, they can implicate state usury caps and lender-licensing rules if the interest rate is high or you are raising across several states. SAFEs sidestep that issue by not being loans.
Tax and Cap-Table Consequences
Taxes quietly tilt the convertible notes vs equity decision. The biggest lever is qualified small business stock (QSBS) under Section 1202. The One Big Beautiful Bill Act, signed July 4, 2025, created a tiered exclusion for QSBS issued after that date: 50% of gain excluded after a three-year hold, 75% after four years, and 100% after five years. It also raised the per-issuer cap to the greater of $15 million or 10x basis and lifted the company’s gross-asset ceiling to $75 million.
Here is the catch: the QSBS clock starts when you actually hold the stock. Money that comes in as a note or SAFE does not start the clock until it converts into shares — so a founder-friendly instrument today can quietly push out a tax benefit tomorrow. A priced equity round, by contrast, starts the clock at closing.
The other consequence is the cap table itself. Stacked convertibles create dilution you may not feel until conversion. Model it before you raise, not after. If you are new to ownership math, start with Cap Table 101. Cannabis founders weighing the same choice under heavier regulatory constraints can work through the operational side with the consulting team at Collateral Base.
Frequently Asked Questions
Is a SAFE the same as a convertible note?
No. A convertible note is debt with interest and a maturity date, while a SAFE is not debt and has neither. Both defer valuation and convert into equity later, but the convertible notes vs equity trade-offs differ because a note can come due.
Which is cheaper and faster to raise on?
Convertible instruments are almost always cheaper and faster. A SAFE can close in days on a short form, while a priced equity round requires a term sheet, a valuation, and full financing documents.
Does the convertible notes vs equity choice affect QSBS?
Yes. The QSBS holding period under Section 1202 begins when you hold stock. A note or SAFE does not start the clock until it converts, whereas a priced equity round starts it at closing.
How much dilution should I expect?
It depends on the valuation cap and discount, and on how many instruments stack before they convert. Post-money SAFEs shift more of the dilution onto founders, so model your fully diluted cap table before signing.
Next Steps
The convertible notes vs equity decision sets your ownership, your investor relationships, and your tax position for years. The right answer depends on your stage, your investors, and your goals — not on whatever template a friend forwarded you.
Talk it through before you raise. Contact Howard East to structure your round. If a financing later turns into a founder or investor dispute, the litigation team at Howard Law Group can help.
This article is general information, not legal advice. No attorney-client relationship is created by reading it. Attorney Advertising.
